Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Moderna just received fantastic news.

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

VWAP resistance, R&D wins, Q1 revenue surge, and mRNA-1010 risks missed flu contracts—the rating shifts to Sell. Click for an ...

Moderna Inc.’s influenza vaccine made with mRNA technology was recommended for approval by outside advisers to the US Food and Drug Administration, a positive development for what has been a ...